Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/121415
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry |
Author: | Jo, H.E. Corte, T.J. Glaspole, I. Grainge, C. Hopkins, P.M.A. Moodley, Y. Reynolds, P.N. Chapman, S. Walters, E.H. Zappala, C. Allan, H. Keir, G.J. Cooper, W.A. Mahar, A.M. Ellis, S. MacAnsh, S. Goh, N.S. |
Citation: | BMC Pulmonary Medicine, 2019; 19(1):84-84 |
Publisher: | BioMed Central |
Issue Date: | 2019 |
ISSN: | 1471-2466 1471-2466 |
Statement of Responsibility: | Helen E. Jo, Tamera J. Corte, Ian Glaspole, Christopher Grainge, Peter M. A. Hopkins ... Peter A. Bampton ... et al. |
Abstract: | BACKGROUND AND OBJECTIVE:Gastroesophageal reflux disease (GORD) is highly prevalent in idiopathic pulmonary fibrosis (IPF) and may play a role in its pathogenesis. Recent IPF treatment guidelines suggest that all patients with IPF be considered for antacid therapy. However, emerging evidence suggests that antacid therapy does not improve IPF patient outcomes and may increase the risk of pulmonary infection. METHODS:Using prospectively collected data from the Australian IPF Registry including use of antacid therapy, GORD diagnosis and GORD symptoms, the relationship of these GORD variables to survival and disease progression was assessed. The severity of GORD symptoms using the frequency scale for symptoms of GORD (FSSG) and its relationships to outcomes was also assessed for the first time in an IPF cohort. RESULTS:Five hundred eighty-seven (86%) of the 684 patients in the Australian IPF Registry were eligible for inclusion. Patients were mostly male (69%), aged 71.0 ± 8.5 years with moderate disease (FVC 81.7 ± 21.5%; DLco 48.5 ± 16.4%). Most patients were taking antacids (n = 384; 65%), though fewer had a diagnosis of GORD (n = 243, 41.4%) and typical GORD symptoms were even less common (n = 171, 29.1%). The mean FSSG score was 8.39 ± 7.45 with 43% (n = 251) having a score > 8. Overall, there was no difference in survival or disease progression, regardless of antacid treatment, GORD diagnosis or GORD symptoms. CONCLUSIONS:Neither the use of antacid therapy nor the presence of GORD symptoms affects longer term outcomes in IPF patients. This contributes to the increasing evidence that antacid therapy may not be beneficial in IPF patients and that GORD directed therapy should be considered on an individual basis to treat the symptoms of reflux. |
Keywords: | Antacid Cough Gastroesophageal reflux disease Idiopathic pulmonary fibrosis Registry |
Rights: | © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
DOI: | 10.1186/s12890-019-0846-2 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/1066128 |
Published version: | http://dx.doi.org/10.1186/s12890-019-0846-2 |
Appears in Collections: | Aurora harvest 4 Medicine publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_121415.pdf | Published version | 750.21 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.